Literature DB >> 30342028

Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium.

Madhav Desai1, David A Lieberman2, Kevin F Kennedy3, Nour Hamade1, Prashanthi Thota4, Sravanthi Parasa5, Venkat Subhash Gorrepati3, Ajay Bansal1, Neil Gupta6, Srinivas Gaddam7, Patrick E Young8, Sharad Mathur9, Fouad J Moawad8, Brooks D Cash10, Richard Sampliner11, John J Vargo4, Gary W Falk12, Prateek Sharma13.   

Abstract

INTRODUCTION: Data on time trends of dysplasia and esophageal adenocarcinoma (EAC) in Barrett's esophagus (BE) during the index endoscopy (ie, prevalent cases) are limited. Our aim was to determine the prevalence patterns of BE-associated dysplasia on index endoscopy over the past 25 years.
METHODS: The Barrett's Esophagus Study is a multicenter outcome project of a large cohort of patients with BE. Proportions of patients with index endoscopy findings of no dysplasia (NDBE), low-grade dysplasia (LGD), high-grade dysplasia (HGD), and EAC were extracted per year of index endoscopy, and 5-yearly patient cohorts were tabulated over years 1990 to 2010+ (2010-current). Prevalent dysplasia and endoscopic findings were trended over the past 25 years using percentage dysplasia (LGD, HGD, EAC, and HGD/EAC) to assess changes in detection of BE-associated dysplasia over the last 25 years. Statistical analysis was done using SAS version 9.4 software (SAS, Cary, NC).
RESULTS: A total of 3643 patients were included in the analysis with index endoscopy showing NDBE in 2513 (70.1%), LGD in 412 (11.5%), HGD in 193 (5.4%), and EAC in 181 (5.1%). Over time, there was an increase in the mean age of patients with BE (51.7 ± 29 years vs 62.6 ± 11.3 years) and the proportion of males (84% vs 92.6%) diagnosed with BE but a decrease in the mean BE length (4.4±4.3 cm vs 2.9±3.0 cm) as time progressed (1990-1994 to 2010-2016 time periods). The presence of LGD on index endoscopy remained stable over 1990 to 2016. However, a significant increase (148% in HGD and 112% in EAC) in the diagnosis of HGD, EAC, and HGD/EAC was noted on index endoscopy over the last 25 years (P < .001). There was also a significant increase in the detection of visible lesions on index endoscopy (1990-1994, 5.1%; to 2005-2009, 6.3%; and 2010+, 16.3%) during the same period.
CONCLUSION: Our results suggest that the prevalence of HGD and EAC has significantly increased over the past 25 years despite a decrease in BE length during the same period. This increase parallels an increase in the detection of visible lesions, suggesting that a careful examination at the index examination is crucial.
Copyright © 2019 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30342028      PMCID: PMC7053563          DOI: 10.1016/j.gie.2018.09.041

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  31 in total

1.  The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy.

Authors:  H B El-Serag; T Aguirre; M Kuebeler; R E Sampliner
Journal:  Aliment Pharmacol Ther       Date:  2004-06-15       Impact factor: 8.171

Review 2.  Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis.

Authors:  Kavel Visrodia; Siddharth Singh; Rajesh Krishnamoorthi; David A Ahlquist; Kenneth K Wang; Prasad G Iyer; David A Katzka
Journal:  Gastroenterology       Date:  2015-11-24       Impact factor: 22.682

3.  Increasing incidence of Barrett's oesophagus: a population-based study.

Authors:  Helen G Coleman; Shivaram Bhat; Liam J Murray; Damian McManus; Anna T Gavin; Brian T Johnston
Journal:  Eur J Epidemiol       Date:  2011-06-14       Impact factor: 8.082

4.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.

Authors:  Heiko Pohl; H Gilbert Welch
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

5.  Temporal changes in the endoscopic frequency of new cases of Barrett's esophagus in an Australian health region.

Authors:  Bradley J Kendall; David C Whiteman
Journal:  Am J Gastroenterol       Date:  2006-06       Impact factor: 10.864

6.  Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries.

Authors:  A A Botterweck; L J Schouten; A Volovics; E Dorant; P A van Den Brandt
Journal:  Int J Epidemiol       Date:  2000-08       Impact factor: 7.196

7.  Incidence of adenocarcinoma among patients with Barrett's esophagus.

Authors:  Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

8.  Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota.

Authors:  M Conio; A J Cameron; Y Romero; C D Branch; C D Schleck; L J Burgart; A R Zinsmeister; L J Melton; G R Locke
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

9.  Continuing rapid increase in esophageal adenocarcinoma in England and Wales.

Authors:  Côme Lepage; Bernard Rachet; Valérie Jooste; Jean Faivre; Michel P Coleman
Journal:  Am J Gastroenterol       Date:  2008-10-03       Impact factor: 10.864

10.  Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005.

Authors:  M B Cook; W-H Chow; S S Devesa
Journal:  Br J Cancer       Date:  2009-08-11       Impact factor: 7.640

View more
  3 in total

1.  Microbiota Detection Patterns Correlate With Presence and Severity of Barrett's Esophagus.

Authors:  Ikenna C Okereke; Aaron L Miller; Daniel C Jupiter; Catherine F Hamilton; Gabriel L Reep; Timothy Krill; Clark R Andersen; Richard B Pyles
Journal:  Front Cell Infect Microbiol       Date:  2021-02-23       Impact factor: 5.293

Review 2.  Role of Obesity, Physical Exercise, Adipose Tissue-Skeletal Muscle Crosstalk and Molecular Advances in Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  Jan Bilski; Monika Pinkas; Dagmara Wojcik-Grzybek; Marcin Magierowski; Edyta Korbut; Agnieszka Mazur-Bialy; Gracjana Krzysiek-Maczka; Slawomir Kwiecien; Katarzyna Magierowska; Tomasz Brzozowski
Journal:  Int J Mol Sci       Date:  2022-04-01       Impact factor: 5.923

Review 3.  Management of nondysplastic Barrett's esophagus: When to survey? When to ablate?

Authors:  Max M Puthenpura; Krishna O Sanaka; Yi Qin; Prashanthi N Thota
Journal:  Ther Adv Chronic Dis       Date:  2022-04-12       Impact factor: 5.091

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.